Lv21
190 积分 2024-05-28 加入
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
20天前
已完结
IFN‐α and TNF‐α serum levels and their association with disease severity in Egyptian children and adults with alopecia areata
21天前
已完结
Prurigo nodularis in 2025: Current and emerging treatments
24天前
已完结
IL12B and IL23R polymorphisms are associated with alopecia areata
25天前
已完结
TYK2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded
25天前
已完结
PD-L1 Inhibition With MPDL3280A for Solid Tumors
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?
2个月前
已完结
A Review of Hair Anatomy and Animal Models for Alopecia
3个月前
已关闭
Prevalence of lichen planopilaris and frontal fibrosing alopecia in the United States: an All of Us database analysis
3个月前
已完结
皖公网安备34019202002308
